ePharmaSolutions' ReferralPlus Increases Match Rate For Clinical Trial Volunteers By More than 66% - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
ePharmaSolutions' ReferralPlus Increases Match Rate For Clinical Trial Volunteers By More than 66%

Source: Applied Clinical Trials

ePharmaSolutions, a provider of eClinical solutions, announced positive results of initial pilot studies for its patient matching and triaging solution, ReferralPlus™. ReferralPlus™ was designed by ePharmaSolutions as a tool to match patients who disqualify for one study with others they might qualify for using a geo-therapeutic matching algorithm with other studies listed on their technology.

In 2012, ePharmaSolutions organized more than 30 major pharmaceutical companies and CROs to participate in the pilots to determine if they could help increase enrollment rates by triaging/matching patients who disqualified from one clinical trial to trials listed by other participating sponsors. The pilots started at the end of 2013 with the early results showing a significant improvement in cross-study matching which will offer significant economic advantages to pharmaceutical companies recruiting patients while providing patients with more opportunities to find for the right study.

The pilot data came from three pharmaceutical companies who listed their studies on the CenterWatch™ web listing service and used the ReferralPlus™ screening and matching solution. None of the pilot studies included an advertising outreach budget.

The results are summarized below:

  • 33% of the total patients who screened for one study were eligible for and referred to a study site
  • 18% of patients who disqualified from the first study, pre-qualified and were referred to another study
  • 50% of patients who disqualified for any of the studies listed, registered to be contacted about future studies

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here